NVST envistaco.com: Company Value to Revenue

Official company branding of Envista (NVST)

Production restructuring while maintaining industry-standard status serves as the primary catalyst for dynamics, which determines the current trend of the EV/Sales multiple for Envista Holdings (NVST). Envista Holdings revenues are based on the sale of digital diagnostics and orthodontic bracket systems, while physician trust is secured by the precision of implants. The latest value is recorded as 1445.37, where the volatility of this metric serves as an indicator of market momentum and potential reversals.

envistaco.com (NVST): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

NVST (Nobel Biocare): analytical breakdowns and indicator data

- current quotes and average value forecast:
- cash balance and cash flow data:
Fundamental company valuation:NVST, envistaco.com
Manufactured products of Envista Holdings Corp

Envista Holdings (NVST) maintains stability through the expansion of high-margin implants and aligners across Asian markets. Analyzing the company's enterprise value-to-revenue ratio reveals a market valuation of the business excluding debt, where the upward trend reflects growing confidence in the tech giant's restructuring; however, an excessive premium on this multiple signals a correction risk should global liquidity tighten.

Competitor analysis

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio ICU Medical Corp ICUI|XRAY: EV/Sales Multiple|LMAT (LeMaitre Vascular, Inc.) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue ATRC|STAA (STAAR Surgical) - Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio ChromaDex (NAGE)|Company Value to Revenue ZimVie Inc. ZIMV|EV/Sales Multiple ANGO (angiodynamics.com)|EV/Sales Multiple cerus.com CERS|teknova.com - EV/Sales Multiple|Enterprise Value-to-Sales Ratio Monogram Technologies Inc. (MGRM)|Sharps Technology, Inc. (STSS) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple InfuSystem Inc (INFU)|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple